Detalhe da pesquisa
1.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 390(4): 301-313, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38084760
2.
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
N Engl J Med
; 389(4): 335-347, 2023 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37272512
3.
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1.
Blood
; 2024 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38657201
4.
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
N Engl J Med
; 387(24): 2232-2244, 2022 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36507686
5.
Teclistamab in Relapsed or Refractory Multiple Myeloma.
N Engl J Med
; 387(6): 495-505, 2022 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35661166
6.
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.
Blood
; 141(3): 219-230, 2023 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36095849
7.
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Lancet Oncol
; 25(5): e205-e216, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38697166
8.
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.
Cancer
; 130(6): 886-900, 2024 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37960969
9.
T-cell-engaging bispecific antibodies in cancer.
Lancet
; 402(10396): 142-158, 2023 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37271153
10.
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Blood
; 139(6): 835-844, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34289038
11.
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group.
Lancet Oncol
; 24(7): e293-e311, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414019
12.
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study.
Lancet Oncol
; 24(10): 1119-1133, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37717583
13.
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
Cancer
; 129(13): 2035-2046, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36991547
14.
T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA.
Curr Opin Oncol
; 35(6): 601-611, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37501530
15.
Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma.
Future Oncol
; 19(27): 1823-1840, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37492991
16.
Multiple myeloma.
Lancet
; 397(10272): 410-427, 2021 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33516340
17.
Teclistamab, a B-cell maturation antigenâ×âCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Lancet
; 398(10301): 665-674, 2021 08 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34388396
18.
CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide.
Haematologica
; 107(2): 437-445, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33375774
19.
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(10): 1378-1390, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34529931
20.
Molecular dynamics of targeting CD38 in multiple myeloma.
Br J Haematol
; 193(3): 581-591, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33570193